Trial Profile
An open-label, single center study of oral AMN 107 (nilotinib) in adult patients with imatinib - resistant or - intolerant chronic myeloid leukemia in chronic phase, accelerated phase or blast crisis, previously enrolled in and having completed ENACT (CAMN107A2109) trial in Hungary. [EXTENSION OF 700013077]
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 26 Feb 2013
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 26 Feb 2013 New trial record